Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report). The associated price target remains the same with $42.00.
Justin Walsh has given his Buy rating due to a combination of factors including the promising advancement of RAP-219 through clinical trials. The company has announced that the Phase IIa trial for RAP-219 in refractory focal epilepsy is on track, with topline data expected in the third quarter of 2025. This trial is anticipated to demonstrate a favorable clinical profile, which could significantly boost the company’s prospects.
Additionally, Rapport Therapeutics is preparing to initiate a Phase IIa trial for RAP-219 in bipolar mania, with topline data expected in the first half of 2027. Although the pain indication remains on clinical hold, the company’s robust cash position of $305.3 million provides a solid financial runway through 2026. These developments, along with the potential for RAP technology to prove clinically effective and commercially viable in multiple CNS indications, underpin Walsh’s optimistic outlook and Buy rating.